1.20
-0.04(-3.23%)
Currency In USD
| Previous Close | 1.24 |
| Open | 1.23 |
| Day High | 1.24 |
| Day Low | 1.17 |
| 52-Week High | 5.39 |
| 52-Week Low | 0.83 |
| Volume | 398,931 |
| Average Volume | 494,490 |
| Market Cap | 74.42M |
| PE | -0.75 |
| EPS | -1.59 |
| Moving Average 50 Days | 1.17 |
| Moving Average 200 Days | 1.51 |
| Change | -0.04 |
If you invested $1000 in Pyxis Oncology, Inc. (PYXS) since IPO date, it would be worth $90.91 as of August 20, 2025 at a share price of $1.2. Whereas If you bought $1000 worth of Pyxis Oncology, Inc. (PYXS) shares 3 years ago, it would be worth $459.77 as of August 20, 2025 at a share price of $1.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jun 30, 2025 8:30 PM GMT
BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported today that Pyxis Oncology’s Com
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
GlobeNewswire Inc.
May 14, 2025 11:30 AM GMT
BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executi
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
GlobeNewswire Inc.
Apr 25, 2025 5:17 PM GMT
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic mo